Group 1 - The core viewpoint of the article highlights the financial performance of Sanofi Pharmaceutical, reporting a revenue of RMB 4.356 billion and a net profit attributable to shareholders of RMB 1.358 billion, reflecting a year-on-year increase of 24.6% [1] - The company is recognized as a leading biotechnology firm in China, with a strong focus on the research, development, production, and marketing of biopharmaceutical products [1] - Key commercialized products include various biopharmaceuticals such as Tevaz, rhEPO products, and small molecule drugs like Mandi, with Tevaz holding a 63.0% market share in the platelet reduction treatment market in mainland China as of the first half of 2025 [1] Group 2 - As of June 30, 2025, the company is actively developing 30 key products, with 27 of them being innovative drugs in mainland China, including 18 antibody drugs and 6 other biopharmaceuticals [2] - The company has 14 products in research for hematology/oncology, 10 targeting autoimmune diseases, 3 for nephrology, 2 for dermatology, and 1 for metabolic diseases [2]

Core Viewpoint - Sanofi Pharmaceutical (01530) reported a mid-term performance for the six months ending June 30, 2025, showing a revenue of RMB 4.355 billion, a slight decrease of 0.77% year-on-year, while the profit attributable to shareholders increased by 24.61% to RMB 1.358 billion, with basic earnings per share at RMB 0.57 [1] Group 1: Company Performance - The company is recognized as a leading biotechnology firm in China, with extensive experience in the research, production, and marketing of biopharmaceutical products [1] - The core commercialized products include various biopharmaceuticals such as Tevaz, recombinant human erythropoietin products Yibiao and Saiboer, Yisaipu, and Saiputin, as well as the small molecule drug Mandi [1] - Tevaz is noted as the only commercialized recombinant human thrombopoietin product globally [1] Group 2: Market Position - According to IQVIA, Tevaz held a market share of 63.0% in the treatment market for thrombocytopenia in mainland China during the first half of 2025 [1] - The company has been a market leader in the rhEPO market in mainland China for over twenty years, with a total market share of 41.5% in the first half of 2025 [1] - Yisaipu is recognized as the first tumor necrosis factor α inhibitor product launched in the mainland market [1] - Mandi also holds a dominant position in the minoxidil market in mainland China [1] Group 3: Strategic Development - The company is expanding its treatment areas through internal research and development as well as multiple external strategic collaborations [1]

Group 1 - The core viewpoint of the articles highlights the transformation of Chinese innovative pharmaceutical companies from "technology followers" to key players in the global life sciences landscape, supported by venture capital and favorable policies [1] - Two significant events in the first half of the year include the licensing agreement between 3SBio and Pfizer for the PD-1/VEGF dual antibody SSGJ-707, and the breakthrough of Chinese innovative drugs at the 2025 ASCO conference, showcasing their global competitiveness [1] - The Chinese biotech sector is experiencing a remarkable growth, with a reported 78% increase in the first half of 2025, significantly outperforming global peers, despite the overall market capitalization being only 14%-15% of that of U.S. counterparts [1] Group 2 - Concerns about the "selling seedlings" phenomenon, where early-stage innovative drug developments are transferred to large foreign pharmaceutical companies, are emerging within the industry [2] - The investment community views the integration of Chinese companies into the global pharmaceutical ecosystem positively, as multinational corporations (MNCs) are increasingly acquiring Chinese biotech firms rather than solely relying on European or American companies [2] - The business model of selling early-stage projects to MNCs allows biotech companies to quickly recoup funds and continue developing new projects, which is seen as a mature commercial strategy [3]

[Interim Results Announcement](index=1&type=section&id=Interim%20Results%20Announcement) [Financial Summary](index=1&type=section&id=Financial%20Summary) During the reporting period, the company's revenue slightly decreased, and gross profit consequently declined, but profit attributable to owners of the parent and EBITDA both achieved significant growth, primarily due to positive impacts from non-operating factors Financial Summary for the Six Months Ended June 30, 2025 | Indicator | June 30, 2025 (RMB Million) | June 30, 2024 (RMB Million) | Change (RMB Million) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Revenue | 4,355.5 | 4,389.4 | (33.9) | (0.8%) | | Gross Profit | 3,715.8 | 3,797.4 | (81.6) | (2.1%) | | Gross Profit Margin | 85.3% | 86.5% | -1.2% | - | | Profit Attributable to Owners of the Parent | 1,358.2 | 1,089.9 | 268.3 | 24.6% | | Adjusted Non-Operating Profit Attributable to Owners of the Parent | 1,135.8 | 1,112.4 | 23.4 | 2.1% | | EBITDA | 1,832.5 | 1,641.5 | 191.0 | 11.6% | | Adjusted Non-Operating EBITDA | 1,610.1 | 1,663.9 | (53.8) | (3.2%) | [Interim Condensed Consolidated Financial Statements](index=2&type=section&id=Interim%20Condensed%20Consolidated%20Financial%20Statements) This section presents the unaudited interim condensed consolidated statements of profit or loss, comprehensive income, and financial position for the six months ended June 30, 2025, detailing the company's key financial data including revenue, costs, profit, assets, liabilities, and equity [Statement of Profit or Loss](index=2&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss) The company's revenue slightly decreased during the reporting period, but profit for the period and profit attributable to owners of the parent both achieved significant growth due to reduced income tax expense and increased other income and gains Interim Condensed Consolidated Statement of Profit or Loss (For the Six Months Ended June 30, 2025) | Indicator | 2025 (RMB Thousand) | 2024 (RMB Thousand) | | :--- | :--- | :--- | | Revenue | 4,355,485 | 4,389,445 | | Cost of Sales | (639,680) | (592,052) | | Gross Profit | 3,715,805 | 3,797,393 | | Other Income and Gains | 408,289 | 86,144 | | Selling and Distribution Expenses | (1,615,934) | (1,593,979) | | Administrative Expenses | (283,402) | (201,196) | | Research and Development Costs | (547,523) | (476,230) | | Other Expenses | (25,466) | (40,687) | | Finance Costs | (53,002) | (104,351) | | Profit Before Tax | 1,621,697 | 1,421,868 | | Income Tax Expense | (233,123) | (314,283) | | Profit for the Period | 1,388,574 | 1,107,585 | | Profit Attributable to Owners of the Parent | 1,358,204 | 1,089,942 | | Non-Controlling Interests | 30,370 | 17,643 | | Basic Earnings Per Share | RMB 0.57 | RMB 0.45 | | Diluted Earnings Per Share | RMB 0.56 | RMB 0.45 | [Statement of Comprehensive Income](index=3&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Comprehensive%20Income) Total comprehensive income for the period increased compared to the prior year, primarily driven by higher profit for the period, despite fluctuations in exchange differences Interim Condensed Consolidated Statement of Comprehensive Income (For the Six Months Ended June 30, 2025) | Indicator | 2025 (RMB Thousand) | 2024 (RMB Thousand) | | :--- | :--- | :--- | | Profit for the Period | 1,388,574 | 1,107,585 | | Exchange Differences on Translation of Overseas Operations | (45,640) | 6,389 | | Equity Investments Designated at Fair Value Through Other Comprehensive Income: Fair Value Changes | 31,496 | 48,473 | | Other Comprehensive Income for the Period, Net of Tax | (14,144) | 54,862 | | Total Comprehensive Income for the Period | 1,374,430 | 1,162,447 | | Total Comprehensive Income Attributable to Owners of the Parent | 1,344,060 | 1,144,804 | | Non-Controlling Interests | 30,370 | 17,643 | [Statement of Financial Position](index=4&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2025, the company's total assets and net assets both increased, with a significant reduction in current liabilities, leading to substantial improvements in net current assets and current ratio Interim Condensed Consolidated Statement of Financial Position (As of June 30, 2025) | Indicator | June 30, 2025 (RMB Thousand) | December 31, 2024 (RMB Thousand) | | :--- | :--- | :--- | | **Non-Current Assets** | | | | Property, Plant and Equipment | 5,003,774 | 4,993,461 | | Goodwill | 4,237,631 | 4,252,618 | | Total Non-Current Assets | 14,000,000 | 14,865,806 | | **Current Assets** | | | | Inventories | 902,817 | 795,191 | | Trade and Bills Receivables | 1,490,704 | 1,305,160 | | Cash and Cash Equivalents | 1,723,977 | 2,142,651 | | Total Current Assets | 9,830,263 | 9,346,934 | | **Current Liabilities** | | | | Trade and Bills Payables | 217,250 | 179,561 | | Interest-Bearing Bank and Other Borrowings | 1,798,774 | 2,243,750 | | Bonds Payable | — | 1,226,098 | | Total Current Liabilities | 4,203,103 | 5,463,524 | | Net Current Assets | 5,627,160 | 3,883,410 | | Total Assets Less Current Liabilities | 19,627,160 | 18,749,216 | | **Non-Current Liabilities** | | | | Total Non-Current Liabilities | 683,839 | 712,886 | | **Equity** | | | | Net Assets | 18,943,321 | 18,036,330 | | Equity Attributable to Owners of the Parent | 16,319,393 | 15,436,258 | | Non-Controlling Interests | 2,623,928 | 2,600,072 | | Total Equity | 18,943,321 | 18,036,330 | [Notes to the Interim Condensed Consolidated Financial Information](index=6&type=section&id=Notes%20to%20the%20Interim%20Condensed%20Consolidated%20Financial%20Information) This section provides detailed notes to the interim condensed consolidated financial information, covering specific explanations and analyses of changes in company information, accounting policies, operating segments, revenue, expenses, taxes, dividends, earnings per share, balance sheet items, and borrowings [Company Information](index=6&type=section&id=Company%20Information) 3SBio is an investment holding company incorporated in the Cayman Islands, with shares listed on the Main Board of the Hong Kong Stock Exchange, primarily engaged in the development, manufacturing, marketing, and sales of biopharmaceutical products in mainland China - The company was incorporated as an exempted company in the Cayman Islands on August 9, 2006, and its shares were listed on the Main Board of the Hong Kong Stock Exchange on June 11, 2015[13](index=13&type=chunk) - For the six months ended June 30, 2025, the company and its subsidiaries were primarily engaged in the development, manufacturing, marketing, and sales of biopharmaceutical products in mainland China[13](index=13&type=chunk) [Basis of Preparation and Changes in Accounting Policies and Disclosures](index=6&type=section&id=Basis%20of%20Preparation%20and%20Changes%20in%20Accounting%20Policies%20and%20Disclosures) The interim condensed consolidated financial information is prepared in accordance with IAS 34 and consistent accounting policies with annual financial statements, with no significant impact from the first-time adoption of IAS 21 amendments during the period - The interim condensed consolidated financial information is prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting" and presented in RMB, with all values rounded to the nearest thousand[14](index=14&type=chunk) - The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the annual consolidated financial statements for the year ended December 31, 2024, with only the first-time adoption of amended International Financial Reporting Standards[15](index=15&type=chunk) - The amendments to International Accounting Standard 21 "Lack of Exchangeability" had no impact on the interim condensed consolidated financial information, as the currencies used by the Group for transactions and functional currencies are all exchangeable[16](index=16&type=chunk) [Operating Segment Information](index=7&type=section&id=Operating%20Segment%20Information) The Group has only one operating segment: the development, manufacturing, marketing, and sales of biopharmaceutical products, with revenue and non-current assets primarily concentrated in mainland China and a diversified customer base without any single major customer - The Group has only one operating segment: the development, manufacturing, marketing, and sales of biopharmaceutical products[17](index=17&type=chunk) Geographical Distribution of Revenue from External Customers (For the Six Months Ended June 30) | Region | 2025 (RMB Thousand) | 2024 (RMB Thousand) | | :--- | :--- | :--- | | Mainland China | 4,215,107 | 4,306,754 | | Other | 140,378 | 82,691 | | Total Revenue | 4,355,485 | 4,389,445 | Geographical Distribution of Non-Current Assets (As of June 30) | Region | June 30, 2025 (RMB Thousand) | December 31, 2024 (RMB Thousand) | | :--- | :--- | :--- | | Mainland China | 10,059,737 | 10,169,932 | | Other | 2,093,239 | 1,960,625 | | Total Non-Current Assets | 12,152,976 | 12,130,557 | - The Group has a diversified customer base, with no single major customer accounting for **10% or more** of total transaction revenue[20](index=20&type=chunk) [Revenue Analysis](index=8&type=section&id=Revenue) The Group's revenue primarily derives from biopharmaceutical sales, with significant growth in contract development and manufacturing operations, and revenue recognition mainly occurs at a point in time when goods are transferred Revenue Analysis (For the Six Months Ended June 30) | Revenue Source | 2025 (RMB Thousand) | 2024 (RMB Thousand) | | :--- | :--- | :--- | | Sales of Biopharmaceutical Products | 4,254,577 | 4,332,185 | | Contract Development and Manufacturing Operations | 100,908 | 57,260 | | Total | 4,355,485 | 4,389,445 | Disaggregated Revenue Information from Customer Contracts (For the Six Months Ended June 30) | Category | 2025 (RMB Thousand) | 2024 (RMB Thousand) | | :--- | :--- | :--- | | **Type of Goods or Services** | | | | Sales of Biopharmaceutical Products | 4,254,577 | 4,332,185 | | Contract Development and Manufacturing Operations | 100,908 | 57,260 | | **Geographical Markets** | | | | Mainland China | 4,215,107 | 4,306,754 | | Other | 140,378 | 82,691 | | **Timing of Revenue Recognition** | | | | Goods Transferred at a Point in Time | 4,254,577 | 4,332,185 | | Services Transferred at a Point in Time | 100,908 | 57,260 | [Other Income and Gains](index=9&type=section&id=Other%20Income%20and%20Gains) Other income and gains significantly increased this period, primarily driven by fair value gains on financial assets measured at fair value through profit or loss, alongside stable contributions from interest income and government grants Other Income and Gains Analysis (For the Six Months Ended June 30) | Item | 2025 (RMB Thousand) | 2024 (RMB Thousand) | | :--- | :--- | :--- | | **Other Income** | | | | Interest Income | 83,937 | 81,224 | | Government Grants - Assets | 14,948 | 15,860 | | Government Grants - Income | 28,381 | 19,568 | | Other | 11,803 | 12,967 | | Total Other Income | 139,069 | 129,619 | | **Gains** | | | | Gain on Disposal of a Subsidiary | 2,614 | — | | Gain on Disposal of Intangible Assets | 79 | — | | Net Exchange Differences | 9,515 | 12,092 | | Fair Value Gains/(Losses) on Financial Assets at Fair Value Through Profit or Loss | 257,012 | (55,567) | | Total Gains | 269,220 | (43,475) | | Total Other Income and Gains | 408,289 | 86,144 | [Expense Analysis](index=10&type=section&id=Expense%20Analysis) Cost of inventories sold, depreciation, amortization, and employee benefit expenses all increased this period, with share-based payment expenses being a new item, while donations and losses on disposal of property, plant, and equipment decreased Items Deducted From/(Credited to) Profit Before Tax (For the Six Months Ended June 30) | Item | 2025 (RMB Thousand) | 2024 (RMB Thousand) | | :--- | :--- | :--- | | Cost of Inventories Sold | 564,704 | 535,261 | | Cost of Services Provided | 74,976 | 56,791 | | Depreciation of Property, Plant and Equipment | 163,933 | 122,759 | | Amortization of Other Intangible Assets | 57,836 | 53,361 | | Depreciation of Right-of-Use Assets | 12,837 | 11,269 | | Amortization of Long-Term Deferred Expenses | 7,089 | 9,069 | | Employee Benefit Expenses | 810,218 | 773,934 | | Share-Based Payment Expenses | 59,856 | — | | Donations | 4,061 | 17,531 | | Loss on Lease Termination | 236 | — | | Loss on Disposal of Property, Plant and Equipment | 8,333 | 12,533 | | Impairment (Reversal)/Provision for Trade Receivables | (1,933) | 799 | | Impairment Provision for Prepayments, Other Receivables and Other Assets | 5,717 | 4,494 | | Other | 9,052 | 5,330 | | Total (Other Expenses and Losses) | 25,466 | 40,687 | [Finance Costs](index=10&type=section&id=Finance%20Costs) Finance costs significantly decreased this period, primarily due to reduced interest expenses on bank borrowings Finance Costs Analysis (For the Six Months Ended June 30) | Item | 2025 (RMB Thousand) | 2024 (RMB Thousand) | | :--- | :--- | :--- | | Interest on Bank Borrowings | 27,824 | 77,661 | | Interest on Bonds Payable | 24,307 | 25,132 | | Interest on Lease Liabilities | 871 | 1,558 | | Total | 53,002 | 104,351 | [Income Tax](index=11&type=section&id=Income%20Tax) The Group's income tax expense significantly decreased, and the effective tax rate declined, primarily benefiting from preferential tax rates for high-tech enterprises in mainland China and reduced non-deductible expenses - The company and its subsidiaries are **exempt from income tax** in the Cayman Islands and British Virgin Islands, and there was no assessable profit in Hong Kong[24](index=24&type=chunk) - Chinese subsidiaries (such as Shenyang 3SBio, Saibaoer Bio, 3SBio Mandi, Antibody Center, and 3SBio Guojian) qualify as high-tech enterprises, enjoying a **preferential income tax rate of 15%**, while other Chinese subsidiaries are taxed at **25%**[25](index=25&type=chunk)[26](index=26&type=chunk) - Sirton Pharmaceuticals S.p.A. is subject to income tax at a rate of **27.9%**[26](index=26&type=chunk) Income Tax Provision Analysis (For the Six Months Ended June 30) | Item | 2025 (RMB Thousand) | 2024 (RMB Thousand) | | :--- | :--- | :--- | | Current | 199,935 | 308,218 | | Deferred | 33,188 | 6,065 | | Total Tax Expense for the Period | 233,123 | 314,283 | [Dividends](index=11&type=section&id=Dividends) The Board recommended a final dividend of HKD 25 cents per share for 2024, approved at the 2025 AGM, but not yet paid during the reporting period Dividends (For the Six Months Ended June 30) | Item | 2025 (RMB Thousand) | 2024 (RMB Thousand) | | :--- | :--- | :--- | | 2024 Final - HKD 25 cents per share | 547,149 | — | | 2023 Final - HKD 25 cents per share | — | 551,834 | - The Board recommended a final dividend of **HKD 25 cents per share** for 2024 on March 25, 2025, which was approved at the Annual General Meeting on June 25, 2025, but had not yet been paid to shareholders during the reporting period[28](index=28&type=chunk) [Earnings Per Share Attributable to Owners of the Parent](index=12&type=section&id=Earnings%20Per%20Share%20Attributable%20to%20Owners%20of%20the%20Parent) Both basic and diluted earnings per share increased this period, reflecting the rise in profit attributable to owners of the parent Basis for Calculating Basic and Diluted Earnings Per Share (For the Six Months Ended June 30) | Item | 2025 (RMB Thousand) | 2024 (RMB Thousand) | | :--- | :--- | :--- | | **Profit** | | | | Profit Attributable to Ordinary Equity Holders of the Parent Used for Basic EPS Calculation | 1,358,204 | 1,089,942 | | **Number of Shares** | | | | Weighted Average Number of Ordinary Shares in Issue for Basic EPS Calculation | 2,397,136,743 | 2,429,790,687 | | Dilutive Effect - Weighted Average Number of Ordinary Shares: Share Options | 4,902,710 | — | | Dilutive Effect - Weighted Average Number of Ordinary Shares: Awarded Shares | 43,107,688 | 2,750,000 | | Total (Diluted Weighted Average Number) | 2,445,147,141 | 2,432,540,687 | - Basic earnings per share was **RMB 0.57** (2024: RMB 0.45), and diluted earnings per share was **RMB 0.56** (2024: RMB 0.45)[5](index=5&type=chunk)[10](index=10&type=chunk) [Property, Plant and Equipment](index=13&type=section&id=Property%2C%20Plant%20and%20Equipment) The Group's carrying value of property, plant and equipment slightly increased, primarily due to additions, partially offset by depreciation and disposals, with some land and buildings pledged for bank financing Changes in Carrying Value of Property, Plant and Equipment (As of June 30) | Item | June 30, 2025 (RMB Thousand) | December 31, 2024 (RMB Thousand) | | :--- | :--- | :--- | | Carrying Value at January 1 | 4,993,461 | 4,692,152 | | Additions | 167,631 | 591,493 | | Depreciation Charged During the Period/Year | (163,933) | (259,729) | | Disposals | (11,726) | (23,651) | | Exchange Adjustments | 18,341 | (6,804) | | Carrying Value at June 30/December 31 | 5,003,774 | 4,993,461 | - As of June 30, 2025, approximately **RMB 2,938,000** of freehold land is located in Italy[31](index=31&type=chunk) - Certain freehold land and buildings of the Group, with a total carrying value of approximately **RMB 2,938,000** and **RMB 33,143,000** respectively, have been pledged as collateral for bank financing[32](index=32&type=chunk) [Trade and Bills Receivables](index=13&type=section&id=Trade%20and%20Bills%20Receivables) The Group's net trade and bills receivables increased, with credit terms generally two to three months, maintained under strict control, and no significant concentration of credit risk Trade and Bills Receivables Analysis (As of June 30) | Item | June 30, 2025 (RMB Thousand) | December 31, 2024 (RMB Thousand) | | :--- | :--- | :--- | | Trade Receivables | 1,462,346 | 1,312,969 | | Bills Receivables | 79,808 | 45,574 | | Total | 1,542,154 | 1,358,543 | | Impairment Provision for Trade Receivables | (51,450) | (53,383) | | Net Carrying Amount | 1,490,704 | 1,305,160 | - The Group's trade terms with customers are primarily on credit, with a general credit period of **two months**, extendable to a maximum of **three months** for major customers[33](index=33&type=chunk) Ageing Analysis of Trade Receivables (As of June 30) | Ageing | June 30, 2025 (RMB Thousand) | December 31, 2024 (RMB Thousand) | | :--- | :--- | :--- | | Within 1 Year | 1,403,616 | 1,260,527 | | 1 to 2 Years | 12,188 | 7,530 | | Over 2 Years | 46,542 | 44,912 | | Total | 1,462,346 | 1,312,969 | [Cash and Cash Equivalents and Pledged Deposits](index=14&type=section&id=Cash%20and%20Cash%20Equivalents%20and%20Pledged%20Deposits) The Group's total cash and cash equivalents slightly increased, primarily denominated in RMB, USD, and EUR, with some deposits pledged to provide security Cash and Cash Equivalents and Pledged Deposits Analysis (As of June 30) | Item | June 30, 2025 (RMB Thousand) | December 31, 2024 (RMB Thousand) | | :--- | :--- | :--- | | Bank Balances and Cash on Hand | 1,413,284 | 1,618,397 | | Restricted Cash | 310,693 | 524,254 | | Unpledged Time Deposits | 868,231 | 1,621,381 | | Time Deposits with Original Maturity Over Three Months | 1,642,318 | 406,492 | | Pledged Deposits | 134,230 | 178,568 | | Subtotal | 4,368,756 | 4,349,092 | | Cash and Cash Equivalents | 1,723,977 | 2,142,651 | Currency Denomination of Cash and Cash Equivalents and Deposits (As of June 30) | Currency | June 30, 2025 (RMB Thousand) | December 31, 2024 (RMB Thousand) | | :--- | :--- | :--- | | RMB | 2,657,932 | 2,953,324 | | HKD | 63,985 | 39,986 | | USD | 1,472,441 | 1,211,301 | | EUR | 174,157 | 144,315 | | JPY | 15 | 2 | | AUD | 226 | 163 | | GBP | — | 1 | | Total | 4,368,756 | 4,349,092 | - As of June 30, 2025, approximately **RMB 134,230,000** of deposits were pledged to secure letters of credit, bank acceptance bills, pending litigation, and arbitration[37](index=37&type=chunk) [Trade and Bills Payables](index=15&type=section&id=Trade%20and%20Bills%20Payables) The Group's total trade and bills payables increased, primarily concentrated within three months maturity, and are non-interest bearing Ageing Analysis of Trade and Bills Payables (As of June 30) | Ageing | June 30, 2025 (RMB Thousand) | December 31, 2024 (RMB Thousand) | | :--- | :--- | :--- | | Within 3 Months | 162,070 | 152,171 | | 3 to 6 Months | 49,132 | 24,752 | | Over 6 Months | 6,048 | 2,638 | | Total | 217,250 | 179,561 | - Trade and bills payables are **non-interest bearing** and repayable within the normal operating cycle or on demand[38](index=38&type=chunk) [Interest-bearing Bank and Other Borrowings](index=16&type=section&id=Interest-bearing%20Bank%20and%20Other%20Borrowings) The Group's total interest-bearing bank and other borrowings significantly decreased, primarily due to loan repayments, with borrowings denominated in RMB, HKD, and EUR, and some secured Interest-Bearing Bank and Other Borrowings Analysis (As of June 30) | Item | June 30, 2025 (RMB Thousand) | December 31, 2024 (RMB Thousand) | | :--- | :--- | :--- | | **Current** | | | | Bank Loans - Unsecured | 400,239 | 1,993,750 | | Bank Loans - Secured | 1,398,535 | 250,000 | | Subtotal - Current | 1,798,774 | 2,243,750 | | Bonds Payable | — | 1,226,098 | | Total - Current | 1,798,774 | 3,469,848 | | **Non-Current** | | | | Bank Loans - Secured | 37,811 | 37,628 | | Total - Non-Current | 37,811 | 37,628 | | Total | 1,836,585 | 3,507,476 | Currency Denomination of Interest-Bearing Bank Borrowings (As of June 30) | Currency | June 30, 2025 (RMB Thousand) | December 31, 2024 (RMB Thousand) | | :--- | :--- | :--- | | RMB | 1,798,774 | 800,374 | | HKD | — | 721,367 | | EUR | 37,811 | 759,637 | | Total | 1,836,585 | 2,281,378 | - Bank borrowings bear interest at fixed annual rates ranging from **1.70% to 2.75%** (December 31, 2024: 2.10% to 3.03%)[42](index=42&type=chunk) - Certain bank borrowings of the Group are secured by mortgages over its own land and buildings[42](index=42&type=chunk) [Bonds Payable](index=17&type=section&id=Bonds%20Payable) The Group redeemed RMB 1,200,000,000 of unsecured unlisted Panda bonds during the reporting period, resulting in no outstanding bonds as of June 30, 2025 - The company issued unsecured unlisted Panda bonds totaling **RMB 1,200,000,000** on June 26, 2023, bearing a fixed annual interest rate of **4.20%**[40](index=40&type=chunk) - The company redeemed these bonds on June 25, 2025, thus having **no outstanding bonds payable** as of June 30, 2025[40](index=40&type=chunk)[41](index=41&type=chunk) [Share Capital](index=18&type=section&id=Share%20Capital) Issued share capital slightly increased this period due to the exercise of share options, while the declared 2024 final dividend was paid from the share premium account Overview of Changes in Issued Share Capital (For the Six Months Ended June 30, 2025) | Item | Number of Shares Issued | Share Capital (RMB Thousand) | Share Premium (RMB Thousand) | Total (RMB Thousand) | | :--- | :--- | :--- | :--- | :--- | | As of December 31, 2024 and January 1, 2025 | 2,395,573,912 | 146 | 2,729,341 | 2,729,487 | | Shares Issued Upon Exercise of Share Options | 4,012,500 | —* | 40,409 | 40,409 | | 2024 Final Dividend Declared | — | — | (547,149) | (547,149) | | As of June 30, 2025 | 2,399,586,412 | 146 | 2,222,601 | 2,222,747 | - The company paid the 2024 final dividend from the share premium account[44](index=44&type=chunk) [Management Discussion and Analysis](index=19&type=section&id=Management%20Discussion%20and%20Analysis) This section elaborates on the company's business performance, key strategic collaborations, R&D progress, core product market position, CDMO business development, sales and marketing strategies, and future industry outlook, alongside an in-depth analysis of financial data [Business Review](index=19&type=section&id=Business%20Review) As a leading biotechnology company in China, the Group possesses extensive experience in R&D, manufacturing, and marketing biopharmaceutical products, with core products holding leading market shares, continuously expanding its pipeline and therapeutic areas through strategic collaborations and independent R&D [Overview](index=19&type=section&id=Overview) 3SBio is a leading biotechnology company in China with extensive experience in biopharmaceutical R&D, manufacturing, and marketing, featuring core commercialized products like TPIAO, EPIAO, SAIBOER, Yisaipu, Saiputing, and Mandi, holding dominant market positions in various therapeutic areas - **TPIAO** is the world's only commercialized recombinant human thrombopoietin (rhTPO) product, holding a **63.0% market share** in mainland China's thrombocytopenia treatment market in H1 2025[45](index=45&type=chunk) - **EPIAO** and **SAIBOER**, two rhEPO products, have made the Group a leader in mainland China's rhEPO market for over two decades, collectively holding a **41.5% market share** in H1 2025[45](index=45&type=chunk) - **Yisaipu** was the first tumor necrosis factor (TNF) α inhibitor product launched in mainland China, and **Mandi** also holds a dominant position in mainland China's minoxidil market[45](index=45&type=chunk) [Significant Events](index=19&type=section&id=Significant%20Events) This period, the company achieved significant progress in HER2 ADC drug collaboration, 707 injection breakthrough therapy designation, and a global licensing agreement and new share subscription with Pfizer, substantially enhancing its R&D capabilities and international influence - A collaboration agreement was reached with RemeGen for the HER2 ADC drug **DB-1303**, granting Shenyang 3SBio commercialization rights in mainland China, Hong Kong, and Macau[46](index=46&type=chunk) - The self-developed **707 injection** (anti-VEGF/PD-1 bispecific antibody) was granted breakthrough therapy designation by China's NMPA for first-line treatment of PD-L1 positive locally advanced or metastatic small cell lung cancer[47](index=47&type=chunk) - An exclusive licensing agreement was signed with Pfizer, granting Pfizer global development, manufacturing, and commercialization rights for 707 outside mainland China; the Group will receive an **upfront payment of USD 1,250 million** and up to **USD 4,800 million** in potential milestone payments, plus double-digit tiered royalties[50](index=50&type=chunk)[51](index=51&type=chunk) - Pfizer subscribed for **31,142,500 ordinary shares** of the company, generating approximately **HKD 785.0 million** in proceeds, with **80%** allocated to enriching the global R&D pipeline and improving manufacturing facilities, and **20%** for other general corporate purposes[54](index=54&type=chunk) [Core Product Performance](index=22&type=section&id=Core%20Product%20Performance) The Group's core products TPIAO, EPIAO, Yisaipu, Saiputing, and Mandi maintain leading positions in their respective markets, continuously consolidating and expanding market share through strategies like medical insurance coverage, clinical guideline recommendations, new formulation development, and market education [TPIAO](index=22&type=section&id=TPO) TPIAO, as the world's only commercialized rhTPO product, demonstrates significant efficacy in treating chemotherapy-induced thrombocytopenia (CIT), primary immune thrombocytopenia (ITP), and pediatric ITP, included in the National Medical Insurance Catalog and multiple clinical guidelines, with substantial future growth potential - **TPIAO** is the world's only commercialized rhTPO product, approved for treating CIT, ITP, and pediatric ITP, and has been included in the Class B of the **National Medical Insurance Catalog** since 2017[56](index=56&type=chunk)[57](index=57&type=chunk) - In H1 2025, TPIAO accounted for **63.0%** of mainland China's thrombocytopenia treatment market by sales value and **30.1%** by sales volume[58](index=58&type=chunk) - The Phase III clinical study of TPIAO for treating chronic liver disease-related thrombocytopenia patients reached its primary endpoint, and a marketing application was submitted to the NMPA in August 2024[58](index=58&type=chunk) [EPIAO](index=23&type=section&id=Epiao) EPIAO, an rhEPO product, is approved for anemia caused by chronic kidney disease, chemotherapy-induced anemia, and perioperative red blood cell mobilization, included in the National Medical Insurance Catalog since 2000, and holds a dominant position in mainland China's rhEPO market - **EPIAO** is approved for anemia caused by CKD, CIA, and perioperative red blood cell mobilization, and has been included in the Class B of the **National Medical Insurance Catalog** since 2000[60](index=60&type=chunk) - EPIAO has maintained a superior dominant position in mainland China's rhEPO market since 2002[60](index=60&type=chunk) - EPIAO is currently undergoing registration in multiple countries across Asia, Africa, Europe, South America, and North America[60](index=60&type=chunk) [Yisaipu](index=23&type=section&id=Yisaipu) Yisaipu, mainland China's first TNFα inhibitor, treats rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriasis, is included in the National Medical Insurance Catalog and professional guidelines, with pre-filled syringe launch enhancing market competitiveness - **Yisaipu** was first launched in mainland China in 2005 for RA, with indications later expanded to AS and psoriasis, and has been included in the Class B of the **National Medical Insurance Catalog** since 2017[61](index=61&type=chunk) - Yisaipu is the first TNFα inhibitor product launched in mainland China, with its efficacy and safety validated in the Chinese market over **twenty years**[61](index=61&type=chunk) - The launch of Yisaipu pre-filled syringes in 2023 provides convenience for patients and enhances overall market competitiveness[62](index=62&type=chunk) [Saiputing](index=24&type=section&id=Saiputing) Saiputing, mainland China's first Fc-modified and process-optimized innovative anti-HER2 monoclonal antibody, is approved for HER2-positive metastatic breast cancer in combination with chemotherapy, included in the National Medical Insurance Catalog and clinical guidelines, showing positive progress in early neoadjuvant and pan-HER2 fields - **Saiputing** is mainland China's first Fc-modified and process-optimized innovative anti-HER2 monoclonal antibody, approved in June 2020 for treating HER2-positive metastatic breast cancer[63](index=63&type=chunk) - Saiputing has been included in the **National Medical Insurance Catalog** since 2020 and is incorporated into multiple clinical guidelines and expert consensuses[63](index=63&type=chunk) - Saiputing has achieved positive research progress in early neoadjuvant therapy, advanced HER2-positive breast cancer treatment, and pan-HER2 applications[63](index=63&type=chunk) [Mandi](index=24&type=section&id=Mandi) Mandi, mainland China's first OTC hair loss drug, is the only topical over-the-counter medication globally approved by FDA and NMPA for male and female hair loss, holding a major share in China's minoxidil market, with future growth driven by market education, digital marketing, and new product specifications - **Mandi** was launched in 2001 as mainland China's first OTC hair loss drug and is the only topical over-the-counter medication globally approved by the FDA and NMPA for treating male and female hair loss[64](index=64&type=chunk) - Mandi has received the **highest recommendation level** in both the "Chinese Guidelines for the Diagnosis and Treatment of Androgenetic Alopecia" and the "Chinese Expert Consensus on the Diagnosis and Treatment of Female Androgenetic Alopecia"[64](index=64&type=chunk) - In H1 2025, Mandi continued to hold a major share in mainland China's minoxidil market, with future growth relying on continuous market education, professional digital marketing systems, and the launch of new product specifications[65](index=65&type=chunk) [CDMO Business](index=25&type=section&id=CDMO%20Business) The Group's CDMO business, comprising Desheng Bio, Shanghai Shengguo Pharmaceutical Development Co., Ltd., Guangdong 3SBio, and Sirton, aims to build international-standard biopharmaceutical CDMO, raw material, and consumable manufacturing bases, specializing in GCT services - The Group's CDMO business is jointly composed of subsidiaries including Desheng Bio, Shanghai Shengguo Pharmaceutical Development Co., Ltd., Guangdong 3SBio, and Sirton in Italy[66](index=66&type=chunk) - Desheng Bio aims to establish a leading domestic and internationally oriented biopharmaceutical CDMO base, biopharmaceutical raw materials and consumables manufacturing base, and biopharmaceutical core process equipment base, all compliant with Chinese, EU, and US GMP regulations[66](index=66&type=chunk) - Guangdong 3SBio focuses on services in the **GCT (Gene and Cell Therapy)** field[66](index=66&type=chunk) [Research and Development](index=25&type=section&id=Research%20and%20Development) The Group possesses an integrated R&D platform and a team of nearly 800 scientists, focusing on innovative biopharmaceutical product development, with 30 key pipeline products in nephrology, oncology, autoimmune, and inflammatory diseases, achieving significant progress across multiple clinical stages [R&D Platform and Strategy](index=25&type=section&id=R%26D%20Platform%20and%20Strategy) The Group's integrated R&D platform covers extensive expertise from antibody discovery to clinical trial management and regulatory filing, with rich experience in developing pharmaceutical products via mammalian cell expression, bacterial expression, and chemical synthesis, focusing on innovative biopharmaceutical products - The Group's integrated R&D platform encompasses a wide range of expertise for discovering and developing various innovative macromolecule and small molecule products, including antibody discovery, molecular cloning, antibody/protein engineering, gene expression, cell line construction, process development, pilot and large-scale production, quality control and assurance, preclinical and clinical trial design and management, and regulatory filing and registration[67](index=67&type=chunk) - The Group has extensive experience in developing various pharmaceutical products, including mammalian cell expression, bacterial expression, and chemical synthesis, with a focus on innovative biopharmaceutical products[67](index=67&type=chunk) - The Group has multiple leading biological products at different clinical development stages in nephrology, oncology, autoimmune and inflammatory diseases, ophthalmology, dermatology, and metabolic diseases[67](index=67&type=chunk) [Pipeline Products](index=26&type=section&id=Pipeline%20Products) As of June 30, 2025, the Group has 30 key pipeline products, 27 of which are developed as innovative drugs in mainland China, covering hematology/oncology, autoimmune diseases, ophthalmic diseases, nephrology, dermatology, and metabolic diseases - As of June 30, 2025, among the **30 key products** actively developed by the Group, **27** are developed as innovative drugs in mainland China, including **18 antibody drugs**, **6 other biological products**, and **6 small molecule drugs**[69](index=69&type=chunk) - Pipeline products cover hematology/oncology (**14 items**), autoimmune diseases/ophthalmic diseases/other diseases (**10 items**), nephrology (**3 items**), dermatology (**2 items**), and metabolic diseases (**1 item**)[69](index=69&type=chunk) - The Group has laid out multiple early-stage research projects in hematology, oncology, and autoimmune fields, covering over a dozen innovative targets for long-term strategic reserves[73](index=73&type=chunk) [Key R&D Progress](index=27&type=section&id=Key%20R%26D%20Progress) The Group achieved significant progress in clinical trials for multiple pipeline products, including several New Drug Application (NDA) submissions, active advancement of multiple Phase III, Phase II, and Phase I clinical trials, and US FDA IND approvals [New Drug Application (NDA) Submission](index=27&type=section&id=New%20Drug%20Application%20(NDA)%20Submission) The Group completed Phase III clinical trials and submitted NDAs for second-generation recombinant rhEPO (SSS06) for chronic renal anemia, and anti-IL-17A mAb (608) and anti-IL-1β mAb (613) also successfully completed Phase III clinical trials and submitted NDAs - **NuPIAO** (second-generation recombinant rhEPO, SSS06) NDA for treating anemia in chronic renal failure is under review, and Phase II clinical study for chemotherapy-induced anemia (CIA) is ongoing[74](index=74&type=chunk) - The Phase III clinical trial of anti-IL-17A mAb (**608**) for moderate-to-severe plaque psoriasis patients successfully met all efficacy endpoints, and the NDA was submitted and accepted in November 2024[74](index=74&type=chunk) - The Phase III clinical trial of anti-IL-1β mAb (**613**) for acute gouty arthritis (AG) has been completed, and the NDA was submitted and accepted in June 2025[75](index=75&type=chunk) [Phase III R&D](index=27&type=section&id=Phase%20III%20R%26D) Multiple products' Phase III clinical trials are progressing smoothly, including anti-VEGF mAb (601A) expected NDA submission, Collatrone (WS204) planned trial completion and NDA submission, and positive results for anti-IL-4Rα mAb (611) and Semaglutide injection Phase III trials - The Phase III clinical trial of anti-VEGF mAb (**601A**) for BRVO has been completed, with an NDA submission expected in 2025[76](index=76&type=chunk) - Patient enrollment for the Phase III bridging clinical trial of **Collatrone (WS204)** for moderate-to-severe acne vulgaris has been completed, with trial completion and NDA submission planned for 2025[76](index=76&type=chunk) - The Phase III clinical trial of anti-IL-4Rα mAb (**611**) for adult atopic dermatitis patients successfully met its primary endpoint, and patient enrollment for the Phase III clinical trial for CRSwNP has been completed[77](index=77&type=chunk) - Patient enrollment for the Phase III clinical trial of **Semaglutide injection** for weight loss indication was completed in February 2025, and data evaluation and marketing application processes are currently underway after treatment administration[78](index=78&type=chunk) [Phase II R&D](index=28&type=section&id=Phase%20II%20R%26D) HIF-117 (SSS17) is actively undergoing Phase II clinical trials in non-dialysis chronic renal anemia patients and approved for postoperative anemia Phase II trials; patient enrollment for anti-NGF antibody (SSS40), anti-PD-1/HER2 bispecific antibody (705), and anti-PD-1/PD-L1 bispecific antibody (706) Phase II clinical trials is ongoing - **HIF-117 (SSS17)** is actively undergoing Phase II clinical trials in non-dialysis chronic renal anemia patients, with Phase II trial completion and Phase III trial initiation planned for 2025[79](index=79&type=chunk) - Patient enrollment for the Phase II clinical trial of anti-NGF antibody (**SSS40**) for treating moderate-to-severe cancer pain with bone metastasis is ongoing[79](index=79&type=chunk) - Patient enrollment for the Phase II clinical trial of anti-PD-1/HER2 bispecific antibody (**705**) for HER-2 positive advanced solid tumors in mainland China is ongoing, and IND approval has been obtained from the US FDA[80](index=80&type=chunk) - The Phase II clinical trial of anti-PD-1/PD-L1 bispecific antibody (**706**) for treating advanced solid tumors is ongoing[80](index=80&type=chunk) [Phase I R&D and New IND Applications](index=28&type=section&id=Phase%20I%20R%26D%20and%20New%20IND%20Applications) Rapamycin nanoparticles (SSS39) Phase I clinical trial is ongoing; Pegsiticase (SSS11) completed Phase Ib, with Sobi advancing SEL-212 BLA; anti-BDCA2 antibody (626), anti-TL1A antibody (627), anti-PD-1/TGF-β bispecific antibody (708), anti-MUC17/CD3/CD28 trispecific antibody (SSS59), and anti-B7H3 antibody/IL15Rα-IL15 fusion protein (SPGL008) all show progress in Phase I trials or IND applications - The Phase I clinical trial of **Rapamycin nanoparticles (SSS39)** is ongoing, expected to be completed in 2025[81](index=81&type=chunk) - **Pegsiticase (SSS11)** has completed its Phase Ib clinical trial in mainland China, and partner Sobi submitted a rolling Biologics License Application (BLA) to the US FDA in July 2024[82](index=82&type=chunk) - Patient enrollment for the Phase Ia clinical trial of anti-BDCA2 antibody (**626**) in mainland China has been completed, showing good safety and PK/PD data, and the US IND application has also been approved[82](index=82&type=chunk) - The Phase I clinical trial of anti-TL1A antibody (**627**) for ulcerative colitis (UC) is recruiting patients, and the US IND application has also been approved by the US FDA[83](index=83&type=chunk) - Phase I clinical trials for anti-PD-1/TGF-β bispecific antibody (**708**), anti-MUC17/CD3/CD28 trispecific antibody (**SSS59**), and anti-B7H3 antibody/IL15Rα-IL15 fusion protein (**SPGL008**) for treating advanced solid tumors are ongoing[83](index=83&type=chunk) [Sales, Marketing and Distribution](index=29&type=section&id=Sales%2C%20Marketing%20and%20Distribution) The Group sells products through its own team and extensive sales and distribution network in nearly 3,000 tertiary hospitals and 7,000 secondary or lower-tier hospitals in mainland China, exports to 20 countries, and Mandi is also sold via retail pharmacies and online stores - The Group's sales and marketing activities particularly emphasize academic promotion, primarily marketing and promoting its main products through its **own team**[84](index=84&type=chunk) - As of June 30, 2025, the Group has an extensive sales and distribution network in mainland China, comprising **3,054 sales and marketing personnel**, thousands of distributors, and third-party promoters[85](index=85&type=chunk) - The Group's products are sold in nearly **3,000 tertiary hospitals** and **7,000 secondary or lower-tier hospitals** and medical institutions, and exported to **20 countries**[85](index=85&type=chunk) [Industry Outlook and Strategy](index=30&type=section&id=Industry%20Outlook%20and%20Strategy) China's pharmaceutical payment system is shifting towards diversified collaboration, supporting innovative drugs and devices; the Group's bispecific antibody SSGJ-707 deal with Pfizer, exceeding USD 6 billion, set records for upfront and total payments in Chinese innovative drug overseas licensing, reflecting international recognition; for H2, the Group will accelerate innovative drug R&D, advance market access for newly approved products, and continue its dual strategy of independent R&D and external collaboration, seeking global partners - China's pharmaceutical payment system is transitioning from "single medical insurance payment" to "multi-party coordinated payment by medical insurance and commercial insurance," opening new payment channels for innovative drugs and devices; the National Healthcare Security Administration issued the "2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog and Commercial Health Insurance Innovative Drug Catalog Adjustment Work Plan," establishing a tiered payment pathway for innovative drugs[86](index=86&type=chunk) - In H1 2025, the transaction value of Chinese innovative drug overseas licensing reached **USD 60.8 billion**; the Group's bispecific antibody product **SSGJ-707** achieved a deal with Pfizer totaling over **USD 6 billion**, with an upfront payment of **USD 1.25 billion**, setting a record for upfront payments in Chinese innovative drug overseas licensing[87](index=87&type=chunk) - Looking ahead to H2, the Group will continue to accelerate early-stage research and clinical development of innovative drugs, especially in oncology, autoimmune, and nephrology fields, and promote market access and academic promotion for newly approved products (such as TAIXIAN® and BAIRUISU®)[88](index=88&type=chunk) - The Group will continue to implement a dual strategy of independent R&D and external collaboration, identifying potential innovative drug collaboration targets, and actively seeking global partners to jointly advance the global development of pipeline products[88](index=88&type=chunk) [Financial Review](index=31&type=section&id=Financial%20Review) This section provides a detailed analysis of key financial indicators for the reporting period, including revenue, costs, gross profit, various expenses, income tax, EBITDA, and net profit, explaining the reasons for their changes [Revenue](index=31&type=section&id=Revenue_FinancialReview) Total revenue slightly decreased this period, primarily due to reduced sales of TPIAO and EPIAO/SAIBOER, but revenue from hair loss products (Mandi) and CDMO business achieved significant growth Revenue Changes (For the Six Months Ended June 30) | Product/Business | 2025 (RMB Million) | 2024 (RMB Million) | Change (RMB Million) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | 4,355.5 | 4,389.4 | (33.9) | (0.8%) | | TPIAO Sales | 2,371.2 | 2,475.9 | (104.7) | (4.2%) | | EPIAO and SAIBOER Sales | 455.4 | 515.7 | (60.3) | (11.7%) | | Hair Loss Segment Sales | 689.9 | 557.2 | 132.7 | 23.8% | | Mandi Sales | 681.5 | 549.8 | 131.7 | 24.0% | | CDMO Business Revenue | 100.9 | 57.3 | 43.6 | 76.1% | | Other Sales | 770.8 | 805.0 | (34.2) | (4.2%) | - TPIAO sales accounted for approximately **54.4%** of the Group's total revenue, EPIAO and SAIBOER combined sales accounted for approximately **10.5%**, and hair loss segment sales accounted for approximately **15.8%**[89](index=89&type=chunk)[90](index=90&type=chunk)[91](index=91&type=chunk) [Cost of Sales](index=32&type=section&id=Cost%20of%20Sales) Cost of sales increased this period, primarily due to higher sales volume of higher-cost products, leading to an increased proportion of total revenue Cost of Sales (For the Six Months Ended June 30) | Indicator | 2025 (RMB Million) | 2024 (RMB Million) | Change (RMB Million) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Cost of Sales | 639.7 | 592.1 | 47.6 | 8.0% | | % of Total Revenue | 14.7% | - | - | - | - The increase in cost of sales was primarily due to the higher sales volume of higher-cost products in the reporting period compared to the same period in 2024[93](index=93&type=chunk) [Gross Profit](index=32&type=section&id=Gross%20Profit) Both gross profit and gross margin decreased this period, reflecting changes in revenue structure and costs Gross Profit (For the Six Months Ended June 30) | Indicator | 2025 (RMB Million) | 2024 (RMB Million) | Change (RMB Million) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Gross Profit | 3,715.8 | 3,797.4 | (81.6) | (2.1%) | | Gross Profit Margin | 85.3% | 86.5% | -1.2% | - | [Other Income and Gains](index=32&type=section&id=Other%20Income%20and%20Gains_FinancialReview) Other income and gains significantly increased this period, primarily benefiting from fair value changes in financial assets measured at fair value through profit or loss Other Income and Gains (For the Six Months Ended June 30) | Indicator | 2025 (RMB Million) | 2024 (RMB Million) | Change (RMB Million) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Other Income and Gains | 408.3 | 86.1 | 322.2 | 374.2% | - The increase was primarily due to fair value changes in financial assets measured at fair value through profit or loss during the reporting period[95](index=95&type=chunk) [Selling and Distribution Expenses](index=33&type=section&id=Selling%20and%20Distribution%20Expenses) Selling and distribution expenses slightly increased this period, with its ratio to revenue also rising Selling and Distribution Expenses (For the Six Months Ended June 30) | Indicator | 2025 (RMB Million) | 2024 (RMB Million) | Change (RMB Million) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Selling and Distribution Expenses | 1,615.9 | 1,594.0 | 21.9 | 1.4% | | % of Revenue | 37.1% | 36.3% | 0.8% | - | [Administrative Expenses](index=33&type=section&id=Administrative%20Expenses) Administrative expenses significantly increased this period, primarily due to higher share-based compensation, leading to a notable rise in its ratio to revenue Administrative Expenses (For the Six Months Ended June 30) | Indicator | 2025 (RMB Million) | 2024 (RMB Million) | Change (RMB Million) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Administrative Expenses | 283.4 | 201.2 | 82.2 | 40.9% | | % of Revenue | 6.5% | 4.6% | 1.9% | - | - The increase in administrative expenses was primarily due to higher share-based compensation[97](index=97&type=chunk) [Research and Development Costs](index=33&type=section&id=Research%20and%20Development%20Costs) R&D costs continued to increase this period, primarily due to accelerated R&D project advancement, with its ratio to revenue also rising Research and Development Costs (For the Six Months Ended June 30) | Indicator | 2025 (RMB Million) | 2024 (RMB Million) | Change (RMB Million) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Research and Development Costs | 547.5 | 476.2 | 71.3 | 15.0% | | % of Revenue | 12.6% | 10.8% | 1.8% | - | - The increase in research and development costs was primarily due to the accelerated advancement of the Group's R&D projects[98](index=98&type=chunk) [Other Expenses and Losses](index=33&type=section&id=Other%20Expenses%20and%20Losses) Other expenses and losses decreased this period, primarily due to reduced donation expenditures Other Expenses and Losses (For the Six Months Ended June 30) | Indicator | 2025 (RMB Million) | 2024 (RMB Million) | Change (RMB Million) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Other Expenses and Losses | 25.5 | 40.7 | (15.2) | (37.3%) | - The decrease was primarily due to reduced donation expenditures[99](index=99&type=chunk) [Finance Costs](index=34&type=section&id=Finance%20Costs_FinancialReview) Finance costs significantly decreased this period, primarily due to reduced interest-bearing bank borrowings Finance Costs (For the Six Months Ended June 30) | Indicator | 2025 (RMB Million) | 2024 (RMB Million) | Change (RMB Million) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Finance Costs | 53.0 | 104.4 | (51.4) | (49.2%) | - The decrease was primarily due to reduced interest-bearing bank borrowings during the reporting period[100](index=100&type=chunk) [Income Tax Expense](index=34&type=section&id=Income%20Tax%20Expense) Income tax expense significantly decreased this period, with a lower effective tax rate, primarily due to reduced non-deductible expenses Income Tax Expense (For the Six Months Ended June 30) | Indicator | 2025 (RMB Million) | 2024 (RMB Million) | Change (RMB Million) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Income Tax Expense | 233.1 | 314.3 | (81.2) | (25.8%) | | Effective Tax Rate | 14.4% | 22.1% | -7.7% | - | - The decrease in the effective tax rate was primarily due to reduced non-deductible expenses in the reporting period compared to the same period in 2024[101](index=101&type=chunk) [EBITDA and Profit Attributable to Owners of the Parent](index=34&type=section&id=EBITDA%20and%20Profit%20Attributable%20to%20Owners%20of%20the%20Parent) Both EBITDA and profit attributable to owners of the parent increased this period, while adjusted non-operating EBITDA slightly decreased EBITDA and Net Profit (For the Six Months Ended June 30) | Indicator | 2025 (RMB Million) | 2024 (RMB Million) | Change (RMB Million) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | EBITDA | 1,832.5 | 1,641.5 | 191.0 | 11.6% | | Adjusted Non-Operating EBITDA | 1,610.1 | 1,663.9 | (53.8) | (3.2%) | | Profit Attributable to Owners of the Parent | 1,358.2 | 1,089.9 | 268.3 | 24.6% | | Adjusted Non-Operating Profit Attributable to Owners of the Parent | 1,135.8 | 1,112.4 | 23.4 | 2.1% | [Earnings Per Share](index=34&type=section&id=Earnings%20Per%20Share_FinancialReview) Basic earnings per share significantly increased this period, reflecting the company's enhanced profitability Basic Earnings Per Share (For the Six Months Ended June 30) | Indicator | 2025 (RMB) | 2024 (RMB) | Change (%) | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share | 0.57 | 0.45 | 26.7% | [Liquidity, Financial and Capital Resources](index=35&type=section&id=Liquidity%2C%20Financial%20and%20Capital%20Resources) The Group maintains ample liquidity, with significant improvements in net current assets and current ratio, and a decrease in leverage ratio; capital expenditures for the next three years are projected for facility maintenance and capacity expansion, funded by internal resources and bank borrowings [Financial Assets Measured at Fair Value](index=35&type=section&id=Financial%20Assets%20Measured%20at%20Fair%20Value) As of June 30, 2025, the Group's financial assets measured at fair value primarily include bank wealth management products, listed and private equity fund investments - Financial assets measured at fair value primarily include bank wealth management products, investments in several listed companies, and private equity funds focused on the healthcare industry[105](index=105&type=chunk) [Net Current Assets](index=35&type=section&id=Net%20Current%20Assets) The Group's net current assets and current ratio significantly increased, primarily due to reduced interest-bearing bank borrowings and repayment of Panda bonds, leading to lower current liabilities Net Current Assets and Current Ratio (As of June 30) | Indicator | June 30, 2025 (RMB Million) | December 31, 2024 (RMB Million) | | :--- | :--- | :--- | | Net Current Assets | 5,627.2 | 3,883.4 | | Current Ratio | 2.3 | 1.7 | - The increase in net current assets and current ratio was primarily due to reduced interest-bearing bank borrowings and the repayment of Panda bonds, leading to a decrease in current liabilities in 2025[107](index=107&type=chunk) [Funding and Treasury Policy, Borrowings and Asset Pledges](index=35&type=section&id=Funding%20and%20Treasury%20Policy%2C%20Borrowings%20and%20Asset%20Pledges) The Group maintains a prudent funding and treasury policy, expecting to finance working capital and capital needs through internal and external financing; total interest-bearing bank borrowings decreased this period, with no outstanding Panda bonds - The company expects to fund its working capital and other capital requirements through a combination of sources, including internal financing and external financing at reasonable market interest rates[108](index=108&type=chunk) Total Interest-Bearing Bank Borrowings (As of June 30) | Indicator | June 30, 2025 (RMB Million) | December 31, 2024 (RMB Million) | | :--- | :--- | :--- | | Total Interest-Bearing Bank Borrowings | 1,836.6 | 2,281.4 | - The decrease in bank borrowings primarily reflects loan repayments of **RMB 2,602.0 million** during the reporting period, partially offset by new bank borrowings of approximately **RMB 2,100.0 million**[109](index=109&type=chunk) - As of June 30, 2025, the Group had **no outstanding Panda bonds**[110](index=110&type=chunk) [Leverage Ratio](index=36&type=section&id=Leverage%20Ratio) The Group's leverage ratio significantly decreased, primarily due to the repayment of outstanding Panda bonds Leverage Ratio (As of June 30) | Indicator | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Leverage Ratio | 9.9% | 19.7% | - The decrease in the leverage ratio was primarily due to the repayment of outstanding Panda bonds during the reporting period[111](index=111&type=chunk) [Contingent Liabilities](index=36&type=section&id=Contingent%20Liabilities) As of June 30, 2025, the Group had no significant contingent liabilities - As of June 30, 2025, the Group had **no significant contingent liabilities**[112](index=112&type=chunk) [Contractual Obligations](index=36&type=section&id=Contractual%20Obligations) The Group's capital commitments slightly decreased Capital Commitments (As of June 30) | Indicator | June 30, 2025 (RMB Million) | December 31, 2024 (RMB Million) | | :--- | :--- | :--- | | Capital Commitments | 876.1 | 901.9 | [Foreign Exchange and Exchange Rate Risk](index=36&type=section&id=Foreign%20Exchange%20and%20Exchange%20Rate%20Risk) The Group primarily operates in mainland China, with daily business conducted in RMB, and no other significant direct foreign exchange fluctuation risks, except for Sirton's operations, exports, international transaction expenses, and foreign currency-denominated bank borrowings/deposits - The Group primarily operates in mainland China, with daily business conducted in RMB, and has no other significant direct foreign exchange fluctuation risks, except for Sirton's operations, the Group's exports, potential international transaction expenses, and bank borrowings and deposits denominated in foreign currencies[114](index=114&type=chunk) - As of June 30, 2025, the Group's bank deposits denominated in foreign currencies primarily included approximately **USD 205.7 million**, **HKD 70.2 million**, and **EUR 20.7 million**[114](index=114&type=chunk) [Major Acquisitions and Disposals](index=36&type=section&id=Major%20Acquisitions%20and%20Disposals) During the reporting period, the Group had no major acquisitions or disposals of subsidiaries, associates, and joint ventures, nor any significant investments - During the reporting period, the Group had **no major acquisitions or disposals** of subsidiaries, associates, and joint ventures[115](index=115&type=chunk) - As of June 30, 2025, the Group had **no significant investments**[116](index=116&type=chunk) [Future Plans for Major Investments or Capital Assets](index=37&type=section&id=Future%20Plans%20for%20Major%20Investments%20or%20Capital%20Assets) The Group projects total capital expenditures of RMB 800 million to RMB 1,000 million over the next three years, primarily for maintaining existing facilities and expanding capacity, funded by internally generated funds and bank borrowings - The Group estimates total capital expenditures of between **RMB 800 million and RMB 1,000 million** over the next three years[117](index=117&type=chunk) - This anticipated capital expenditure will primarily be used for maintaining the Group's existing facilities and expanding production capacity[117](index=117&type=chunk) - The Group expects to fund its capital expenditures through a combination of internally generated funds and bank borrowings[117](index=117&type=chunk) [Employees and Remuneration Policy](index=37&type=section&id=Employees%20and%20Remuneration%20Policy) The Group's employee headcount and staff costs increased; remuneration packages include salaries, bonuses, equity incentives, and allowances, with new share award and share option schemes adopted in June 2025 to incentivize employee contributions Employee Headcount and Staff Costs (As of June 30) | Indicator | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Total Employees | 6,268 | 5,577 | | Staff Costs (RMB Million) | 809.8 | 721.9 | - The Group's remuneration packages typically include salaries, bonuses, equity incentives, and allowances, with salary plans linking employee compensation and rewards to their performance[118](index=118&type=chunk) - The company adopted a new share award scheme and a share option scheme in June 2025, aimed at providing incentives and rewards to eligible participants who contribute to the Group's business success[118](index=118&type=chunk) [Interim Dividend](index=37&type=section&id=Interim%20Dividend) The Board does not recommend the payment of any interim dividend for the reporting period - The Board does not recommend the payment of any interim dividend for the reporting period[119](index=119&type=chunk) [Corporate Governance Practices](index=38&type=section&id=Corporate%20Governance%20Practices) The Group is committed to maintaining high standards of corporate governance and complies with the Corporate Governance Code in the HKEX Listing Rules; although the roles of Chairman and CEO are combined, the Board believes this arrangement facilitates efficient decision-making and will be reviewed periodically [Separation of Roles of Chairman and Chief Executive Officer](index=38&type=section&id=Separation%20of%20Roles%20of%20Chairman%20and%20Chief%20Executive%20Officer) Dr. Lou Jing serves as both Chairman and Chief Executive Officer of the company, an arrangement the Board believes ensures consistent leadership direction and efficient decision-making, and will be reviewed periodically - The company does not distinguish between the Chairman and Chief Executive Officer, with Dr. Lou Jing currently holding both positions concurrently[121](index=121&type=chunk) - The Board believes that combining the roles of Chairman and Chief Executive Officer ensures consistent leadership direction for the Group, leading to more effective and efficient overall strategic planning[121](index=121&type=chunk) - The Board will review and consider separating the roles of Chairman and Chief Executive Officer of the company from time to time, taking into account the Group's overall circumstances[122](index=122&type=chunk) [Standard Code for Securities Transactions by Directors of Listed Issuers](index=38&type=section&id=Standard%20Code%20for%20Securities%20Transactions%20by%20Directors%20of%20Listed%20Issuers) The company adopted the Standard Code for Securities Transactions by Directors of Listed Issuers from Appendix C3 of the HKEX Listing Rules, and all directors confirmed compliance during the reporting period after specific inquiry - The company has adopted the "Standard Code for Securities Transactions by Directors of Listed Issuers" as set out in Appendix C3 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as its code of conduct[123](index=123&type=chunk) - Following specific inquiries made to the directors, all directors confirmed that they complied with the required standards set out in the Standard Code during the reporting period[123](index=123&type=chunk) [Purchase, Sale or Redemption of Listed Securities](index=38&type=section&id=Purchase%2C%20Sale%20or%20Redemption%20of%20Listed%20Securities) During the reporting period, neither the company nor any of its subsidiaries purchased, sold, or redeemed any of the company's listed securities - During the reporting period, neither the company nor any of its subsidiaries purchased, sold, or redeemed any of the company's listed securities[124](index=124&type=chunk) [Audit Committee](index=39&type=section&id=Audit%20Committee) The company's Audit Committee, comprising three independent non-executive directors, reviewed the Group's interim results and assessed the effectiveness of risk management and internal control systems, deeming them effective and adequate - The Board has established the company's Audit Committee, comprising three independent non-executive directors: Mr. Pu Tianruo (Chairman), Mr. Wong Cho Yiu, and Ms. Yang Kaiti[125](index=125&type=chunk) - The Audit Committee has reviewed the Group's unaudited condensed consolidated interim results for the reporting period and assessed the effectiveness of the company's risk management and internal control systems, deeming them effective and adequate[125](index=125&type=chunk) [Work Scope of Ernst & Young](index=39&type=section&id=Work%20Scope%20of%20Ernst%20%26%20Young) The financial information in the Group's interim results announcement has been reviewed by Ernst & Young, confirming consistency with the draft unaudited interim condensed consolidated financial information, though this work does not constitute an assurance engagement - The financial information contained in the Group's interim results announcement for the reporting period has been reviewed by the auditor, Ernst & Young, and confirmed to be consistent with the amounts contained in the Group's draft unaudited interim condensed consolidated financial information[126](index=126&type=chunk) - The work performed by Ernst & Young in this regard does not constitute an assurance engagement conducted in accordance with International Standards on Auditing, International Standards on Review Engagements, or International Standards on Assurance Engagements issued by the International Auditing and Assurance Standards Board[126](index=126&type=chunk) [Publication of I

Core Viewpoint - The Hong Kong stock market for innovative drug companies is experiencing a rebound, with significant gains in stocks such as ABL Bio, WuXi AppTec, Innovent Biologics, BeiGene, and others, alongside a more than 4% increase in the Hong Kong Innovative Drug ETF (513120) [1] Company Overview - Ying Shi Biotechnology submitted its application for a Hong Kong IPO on August 25, seeking to list under Chapter 18A, with CITIC Securities and Jianyin International as joint sponsors [3] - Founded in 2017 and headquartered in Nanjing, Ying Shi Biotechnology focuses on innovative drug development for cancer treatment, specifically addressing drug resistance caused by tumor defenses [3][7] - The company has raised funds through six financing rounds, with a post-money valuation of approximately $306 million (about 2.18 billion RMB) following its C round on August 22 [3] Product Pipeline - Ying Shi Biotechnology's product pipeline includes five candidates, with the core product ifebemtinib being a highly selective FAK inhibitor nearing commercialization [11][12] - Ifebemtinib is currently undergoing multiple clinical development projects in China and has received breakthrough therapy designation from the NMPA for three indications and fast track designation from the FDA for one indication [14] - The company also develops a second-generation selective FAK inhibitor (IN10028) and three antibody-drug conjugates (ADCs) [20][21] Market Context - The global cancer treatment market is projected to reach approximately $262.1 billion, with China's market estimated at $37.2 billion by 2024 [11] - The global selective FAK inhibitor market is expected to grow significantly, with a projected market size of $5.562 billion by 2035 and a compound annual growth rate of 71.7% starting in 2026 [17] Financial Performance - Ying Shi Biotechnology has not generated any revenue from product sales and has incurred losses of 252 million RMB over the past two years [23][24] - The company reported operating losses of 174 million RMB, 143 million RMB, and 27.5 million RMB for the years 2023, 2024, and the first quarter of 2025, respectively [24][25] - As of March 31, 2025, the company had cash and cash equivalents of 134 million RMB, with sufficient operating funds to cover costs for at least the next 12 months [25]

Core Viewpoint - The rise of innovative drugs in China is driven by a combination of national support, industry strength, and capital enthusiasm, marking a significant opportunity comparable to the previous boom in new energy [2][3]. Group 1: Market Dynamics - In the first half of 2025, China approved 43 innovative drugs, a 59% increase year-on-year, with 93% developed by Chinese companies [3]. - The implementation of a "30-day fast-track approval channel" has significantly reduced the clinical trial approval time from several years to within one year [3]. - The total value of "License-out" transactions for innovative drugs reached $48.484 billion in the first half of 2025, surpassing the total for 2024 [4][5]. Group 2: Fund Manager Performance - Zhang Wei, a new fund manager, has achieved a return of 151% in 2025, making her fund the top performer in the market [8][9]. - The performance of innovative drug-themed funds has dominated the public fund rankings, with over 90% of the top 100 funds heavily invested in this sector [8]. - New fund managers, with an average tenure of 3-4 years, have shown remarkable performance, often employing concentrated investment strategies in innovative drugs [12][19]. Group 3: Investment Strategies - New fund managers tend to adopt an "all-in" strategy, heavily concentrating their portfolios in innovative drugs, which can amplify returns during bullish trends [12][19]. - The innovative drug sector is viewed as a sustainable trend, akin to the previous new energy boom, with long-term investment value [7][19]. - The current market sentiment reflects a mix of enthusiasm and caution, as the rapid rise in stock prices has led to concerns about potential corrections [6][19]. Group 4: Challenges and Risks - Despite the strong performance, there are concerns about the sustainability of returns for new fund managers, as historical trends show that those who excel in bull markets may struggle during corrections [19][20]. - The innovative drug sector is characterized by high investment risks, long development cycles, and potential market corrections, which could impact future performance [20][21].

Group 1 - The Hong Kong stock market saw all three major indices rise collectively, with gains exceeding 1.1%, indicating a shift from net selling to net buying by southbound funds [1] - The Hang Seng Index rose by 0.63%, surpassing the 25,000-point mark, while the Hang Seng China Enterprises Index and the Hang Seng Tech Index increased by 0.68% and 0.56%, respectively [1] - Biopharmaceutical stocks, which had recently experienced a downturn, rebounded, with companies like Innovent Biologics, WuXi Biologics, and China Biologic Products leading the innovative drug sector [1] Group 2 - The Hong Kong Innovative Drug Selected ETF (520690) saw a peak increase of over 5% during trading, with a transaction volume exceeding 200 million yuan and a turnover rate above 60%, indicating strong buying interest [1] - Most constituent stocks of the ETF experienced gains, with WuXi Biologics rising over 7%, and other companies like CSPC Pharmaceutical, Innovent Biologics, and Green Leaf Pharmaceutical also seeing increases of over 6% [1] - Several innovative drug companies in Hong Kong have recently initiated placement financing, with total fundraising ranging from hundreds of millions to over 2 billion Hong Kong dollars, primarily aimed at research and development, clinical trials, and commercialization [1] Group 3 - A team in China completed the world's first clinical trial using brain-computer interfaces for precise tumor boundary localization during surgery, enhancing surgical quality and preserving healthy brain tissue [2] - The recent wave of placements reflects the capital market's core demand for "funding sustainability" among innovative drug companies, with leading firms consolidating their R&D and internationalization efforts [2] - The integration of brain-computer interfaces and AI is increasing attention on medical AI, improving surgical navigation and operational efficiency in pre- and post-operative processes [2] Group 4 - The Hong Kong Innovative Drug Selected ETF (520690) tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index, utilizing natural language processing (NLP) to analyze annual reports and patent texts [3] - The ETF systematically excludes CXO (contract research organizations) and "pseudo-innovation" entities, ensuring that all constituent stocks are directly involved in innovative drug R&D and commercialization [3]

Core Viewpoint - The Hong Kong stock market is experiencing a rebound, particularly in the innovative pharmaceutical sector, with significant trading activity in the Hong Kong Innovative Drug ETF (520880) [1] Group 1: Market Performance - The Hong Kong Innovative Drug ETF (520880) saw an intraday price increase of over 4.6%, currently up by 3.25%, with a trading volume nearing 500 million [1] - The Hang Seng Innovative Drug Index has risen by 101.58% year-to-date as of July 31, significantly outperforming the Hang Seng Index and Hang Seng Tech Index by 78.08% and 79.53% respectively [6] Group 2: Company Highlights - China National Pharmaceutical Group reported a 27.2% year-on-year increase in revenue from innovative products, which now account for 44.4% of total revenue, with nearly 20 innovative products expected to be approved between 2025 and 2027 [2] - Innovent Biologics announced FDA approval for its PD-1/IL-2α bispecific antibody IBI363 to commence global Phase III clinical trials for squamous NSCLC [2] Group 3: Industry Outlook - According to China International Capital Corporation, the domestic market for innovative drugs is expected to grow significantly, with a projected revenue of 446 billion by 2030 based on a 30% compound annual growth rate [3] - The overseas market for domestic innovative drugs has seen cumulative contract amounts reaching 193.8 billion, with conservative estimates suggesting potential sales contributions of 14.5 billion [3] - The innovative drug sector is characterized by strong industry trends and investment value, supported by policy initiatives and an accelerating internationalization process [3] Group 4: Stock Performance - Major stocks in the innovative pharmaceutical sector, such as CSPC Pharmaceutical Group and Innovent Biologics, have seen price increases exceeding 6%, while others like China National Pharmaceutical and 3SBio have risen over 5% [4]

Core Insights - The Hang Seng Healthcare Index (HSHCI) has seen a strong increase of 2.89%, with notable gains from stocks such as Times Angel (06699) up 7.60% and WuXi Biologics (02269) up 6.77% [3] - The Hang Seng Healthcare ETF (513060) has also risen by 2.49%, with a recent price of 0.7 yuan, and a cumulative increase of 36.13% over the past three months [3] - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) has surged by 3.31%, with significant contributions from WuXi Biologics (02269) and Innovent Biologics (01801) [5] Market Activity - The Hang Seng Healthcare ETF recorded a turnover of 20.42% and a trading volume of 1.543 billion yuan, indicating active market participation [3] - The Hong Kong Stock Connect Innovative Drug Selection ETF (520690) had a turnover of 26.45% and a trading volume of 90.36 million yuan, reflecting strong market engagement [5] Fundraising and Innovations - Several innovative drug companies in Hong Kong have initiated placement financing, with total fundraising ranging from hundreds of millions to over 2 billion HKD, primarily aimed at R&D and commercialization [6] - A team in China has successfully completed the world's first clinical trial using brain-machine interfaces for precise tumor boundary navigation during surgery, enhancing surgical quality and patient outcomes [6] Institutional Insights - The recent wave of placements indicates a core market demand for "funding sustainability" among innovative drug companies, with leading firms leveraging this to strengthen R&D and international expansion [7] - The integration of brain-machine interfaces and AI technologies is expected to enhance medical procedures and operational efficiencies in healthcare settings [7] ETF Performance - The Hang Seng Healthcare ETF has seen a significant increase in shares, with a growth of 163 million shares over the past week, ranking it among the top comparable funds [10] - The ETF has recorded a net inflow of 40.986 million yuan recently, accumulating a total of 107 million yuan over the past five trading days [11] - The ETF's financing net purchase has reached 2.6577 million yuan this month, with a total financing balance of 274 million yuan [12] Valuation Metrics - The Hang Seng Healthcare ETF's latest price-to-earnings ratio (PE-TTM) stands at 29.44, indicating a valuation below 87.52% of the historical range over the past three years [16] - The Hong Kong Stock Connect Innovative Drug Selection ETF has a PE-TTM of 28.71, also reflecting a low valuation compared to historical data [21]

Core Insights - The Chinese biopharmaceutical industry is poised for significant growth in 2025, driven by increased licensing agreements and international expansion [1][2] - The Hong Kong capital market has seen a surge in investment activity, with a notable increase in IPOs and fundraising amounts [2] - Four key driving factors are identified for the rise of the Chinese biopharmaceutical sector: government support, innovative talent, a vibrant venture capital ecosystem, and a comprehensive infrastructure [3][4] Group 1: Market Performance - In 2024, Chinese biopharmaceutical companies engaged in 94 business development transactions totaling $51.9 billion, accounting for nearly one-third of the global market [1] - The first half of 2025 saw licensing agreements nearing $66 billion, surpassing the total for 2024 [1] - Hong Kong's IPO market led globally in the first half of 2025 with 42 IPOs, raising $13.9 billion, a 700% increase year-on-year [2] Group 2: Driving Factors - Long-term national strategy support positions biotechnology as a key component of China's "strategic emerging industries," with significant funding for basic research and drug approval reforms [3] - The return of overseas talent has fostered innovation, with many scientists and executives establishing biotech firms in China [3] - A robust venture capital ecosystem, including domestic and international funds, plays a crucial role in supporting early-stage innovations [4] Group 3: Challenges and Opportunities - There is a mismatch between China's innovation output and domestic market absorption, with only 5% of the global innovative drug market share [5] - Recent policy changes, such as new procurement regulations favoring innovative drugs, are expected to support the continued development of biotechnology in China [5] - Collaboration with multinational companies and emerging markets is essential for Chinese biopharmaceutical firms to thrive globally [6]